Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U.

Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2.

2.

Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.

Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK.

Neurosurgery. 2012 Feb;70(2):361-70. doi: 10.1227/NEU.0b013e3182314f9d.

PMID:
21841523
3.

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D.

Clin Cancer Res. 2011 Sep 1;17(17):5822-32. doi: 10.1158/1078-0432.CCR-11-1185. Epub 2011 Jul 7.

4.

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB.

Neuro Oncol. 2011 Apr;13(4):401-9. doi: 10.1093/neuonc/noq206. Epub 2011 Feb 15.

5.

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T.

Neurology. 2011 Feb 1;76(5):432-7. doi: 10.1212/WNL.0b013e31820a0a8a.

PMID:
21282590
6.

Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel.

Poincloux R, Collin O, Lizárraga F, Romao M, Debray M, Piel M, Chavrier P.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1943-8. doi: 10.1073/pnas.1010396108. Epub 2011 Jan 18.

7.

Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.

Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, Woodnutt G, Lappe R, Bhat A.

Clin Cancer Res. 2011 Mar 1;17(5):1001-11. doi: 10.1158/1078-0432.CCR-10-2317. Epub 2011 Jan 13.

8.

Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.

Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2010 Oct 27;5(10):e13665. doi: 10.1371/journal.pone.0013665.

9.

TWIST1 promotes invasion through mesenchymal change in human glioblastoma.

Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, González-Herrero I, Sánchez-García I, Silber JR, Horner PJ, Rostomily RC.

Mol Cancer. 2010 Jul 20;9:194. doi: 10.1186/1476-4598-9-194.

10.

The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study.

Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang WT, Lustig RA, Judkins AR, Grady MS, Hahn SM, Koch CJ.

Transl Oncol. 2010 Jun 1;3(3):160-9.

11.

Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells.

Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR.

Cancer Res. 2010 May 1;70(9):3780-90. doi: 10.1158/0008-5472.CAN-09-4439. Epub 2010 Apr 13.

12.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS.

Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049.

13.

Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia.

Cristofaro B, Stone OA, Caporali A, Dawbarn D, Ieronimakis N, Reyes M, Madeddu P, Bates DO, Emanueli C.

Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1143-50. doi: 10.1161/ATVBAHA.109.205468. Epub 2010 Apr 1.

14.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.

J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.

15.

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network.

Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.

16.

The transcriptional network for mesenchymal transformation of brain tumours.

Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A.

Nature. 2010 Jan 21;463(7279):318-25. doi: 10.1038/nature08712. Epub 2009 Dec 23.

17.

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

Gerstner ER, Frosch MP, Batchelor TT.

J Clin Oncol. 2010 Feb 20;28(6):e91-3. doi: 10.1200/JCO.2009.25.0233. Epub 2009 Nov 23. No abstract available.

18.

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.

Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T.

J Neurooncol. 2010 Feb;96(3):423-31. doi: 10.1007/s11060-009-9981-6. Epub 2009 Oct 27.

PMID:
19859666
19.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.

20.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.

Items per page

Supplemental Content

Write to the Help Desk